Lausanne University Hospital / Centre hospitalier universitaire vaudois (CHUV)

Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme (2022) Miehlke S, Schlag C, Lucendo AJ, Biedermann L, Vaquero CS, Schmoecker C, Hayat J, et al. Journal article Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial (2022) Dromain C, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Capdevila J, et al. Conference contribution Meta-GWAS Reveals Novel Genetic Variants Associated with Urinary Excretion of Uromodulin (2022) Joseph CB, Mariniello M, Yoshifuji A, Schiano G, Lake J, Marten J, Richmond A, et al. Journal article Report from the HarmoSter study: impact of calibration on comparability of LC-MS/MS measurement of circulating cortisol, 17OH-progesterone and aldosterone (2022) Fanelli F, Cantu M, Temchenko A, Mezzullo M, Lindner JM, Peitzsch M, Hawley JM, et al. Journal article The neurons that restore walking after paralysis. (2022) Kathe C, Skinnider MA, Hutson TH, Regazzi N, Gautier M, Demesmaeker R, Komi S, et al. Journal article Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis. (2022) Rowald A, Komi S, Demesmaeker R, Baaklini E, Hernandez-Charpak SD, Paoles E, Montanaro H, et al. Journal article Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. (2022) Bettiol A, Urban ML, Bello F, Fiori D, Mattioli I, Lopalco G, Iannone F, et al. Journal article EAPC Core Curriculum for Preventive Cardiology (2022) Wilhelm M, Abreu A, Adami PE, Ambrosetti M, Antonopoulou M, Biffi A, Cavarretta E, et al. Journal article Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. (2022) Zanatta E, Huscher D, Ortolan A, Avouac J, Airo P, Balbir-Gurman A, Siegert E, et al. Journal article Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study (2022) Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, et al. Journal article